Malignant pleural mesothelioma
Drug research and approvals for malignant pleural mesothelioma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 48 studies of malignant pleural mesothelioma are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 3 approved and 1 open orphan designations naming it, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 48
- Trials authorized in Canada: 6
- FDA orphan approvals: 3
- EU medicines: 5
Recruiting Now
Newest start dates first, of 48 recruiting on ClinicalTrials.gov ↗- Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural…NCT07885319 · Phase 1 / Phase 2 · Ruijin Hospital · starts Nov 1, 2026
- TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid TumorsNCT07713732 · Phase 1 · Treeline Biosciences, Inc. · starts Aug 5, 2026
- Evaluation of Skin Tests in Biotherapy AllergiesNCT06971848 · Not applicable · University Hospital, Angers · starts Jun 17, 2026
- Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseNCT07192900 · Phase 1 · David Bartlett, MD · starts Jun 3, 2026
- Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsNCT07443020 · Phase 1 · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · starts May 1, 2026
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerNCT07532902 · Phase 1 · Memorial Sloan Kettering Cancer Center · starts Apr 7, 2026
- Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural…NCT07234058 · Phase 2 · Intergroupe Francophone de Cancerologie Thoracique · starts Apr 2, 2026
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsNCT07277413 · Phase 1 · IDEAYA Biosciences · starts Mar 4, 2026
- Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal MesotheliomaNCT07510815 · Phase 1 / Phase 2 · Beijing Biotech · starts Mar 2, 2026
- Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaNCT07126509 · Not applicable · University of Chicago · starts Dec 2, 2025
Trials Authorized in Canada
Newest first; search them all in Canada trials| Mar 30, 2020 | Phase III randomized trial of pleurectomy/decortication plus chemotherapy with or without adjuvant hemithoracic intensity-modulated pleural radiation therapy…PEMETREXED/CISPLATIN/CARBOPLATIN | NRG ONCOLOGY | Closed |
| Mar 7, 2019 | A phase III, open label, randomized, parallel group study to evaluate the efficacy and safety of intrapleural administration of adenovirus-delivered interferon…RAD-IFN (NADOFARAGENE FIRADENOVEC)/ CELECOXIB/ GEMCITABINE | Ferring Pharmaceuticals | Closed |
| Dec 4, 2015 | A randomized, open-label, active-controlled, phase II study of intravenous anetumab ravtansine (bay 94-9343) or vinorelbine in patients with advanced or…BAY 94-9343 (ANETUMAB RAVTANSINE) / VINORELBINE | Bayer | Closed |
| Aug 7, 2013 | A phase 2, randomized, double-blind study comparing tremelimumab to placebo in second or third-line treatment of subjects with unresectable pleural or…TREMELIMUMAB | MEDIMMUNE LLC | Pending |
| Aug 1, 2013 | A phase II randomized, double-blind, placebo-controlled, multicenter study of vs 6063 in subjects with malignant pleural mesotheliomaVS-6063 | Verastem, Inc. | Ongoing |
| May 24, 2013 | Double blind, randomised, multicentre, phase II study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy…NINTEDANIB (BIBF 1120 ES) | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Oct 2, 2020 | OPDIVO and YERVOYOPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural… | Bristol-Myers Squibb Company | Approved |
| Oct 2, 2020 | OPDIVO and YERVOYYERVOY (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant… | Bristol-Myers Squibb Company | Approved |
| Feb 4, 2004 | AlimtaTreatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for… | Eli Lilly and Company | Approved |
| Aug 22, 2008 | ArenegyrTreatment of malignant pleural mesothelioma | MolMed S.p.A. | Designated |
Medicines Authorised in the EU
Newest first| Jul 22, 2016 | Pemetrexed Fresenius Kabipemetrexed · generic | Fresenius Kabi Deutschland GmbH | EMA ↗ |
| Jan 18, 2016 | Pemetrexed Accordpemetrexed · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jan 18, 2016 | Armisarte (previously Pemetrexed Actavis)pemetrexed | Actavis Group PTC ehf | EMA ↗ |
| Nov 19, 2015 | Pemetrexed Pfizer (previously Pemetrexed Hospira)pemetrexed · generic | Pfizer Europe MA EEIG | EMA ↗ |
| Sep 20, 2004 | Alimtapemetrexed | Eli Lilly Nederland B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA